New data released Monday from a long-term follow-up of a Phase 2b clinical trial suggests that a personalized mRNA vaccine co-developed by Moderna and Merck can substantially reduce the likelihood of melanoma returning in high-risk patients. The findings, tracking 157 patients over five years, mark a significant step in the fight against the deadliest form of skin cancer.
The study enrolled patients with Stage 3 melanoma in Australia and the United States, all of whom had their tumors surgically removed before treatment. Fifty participants received only Keytruda, an immunotherapy drug, while 107 received Keytruda in combination with an experimental personalized vaccine called intismeran autogene, designed using the genetic sequence of each patient's own tumor.
Five-Year Results Show Durable Benefit
After five years, 70% of patients who received the personalized vaccine remained cancer-free, compared to just 49% of those treated with Keytruda alone. The results underscore the potential of individualized mRNA technology to target residual cancer cells that standard treatments may miss.
Dr. Marjorie Green, Senior Vice President and Head of Oncology at Merck Research Laboratories, called the outcomes encouraging. "The risk of disease recurrence remains high for patients with stage III/IV melanoma following surgery," she said in a statement. "These long-term findings show that intismeran autogene in combination with Keytruda provided sustained and durable reductions in the risk of recurrence."
Rising Skin Cancer Rates Add Urgency
The development comes amid a global rise in melanoma cases, with over 330,000 new diagnoses in 2022. In the United States alone, an estimated 112,000 new cases are expected in 2026, along with more than 8,500 deaths, according to the companies' release. The vaccine's promise addresses a critical gap in adjuvant therapy for patients who face persistent risk even after surgery.
The vaccine is created by sequencing a patient's tumor DNA to identify mutations, then encoding that information into mRNA to train the immune system to recognize and attack cancer cells. This personalized approach contrasts with traditional one-size-fits-all treatments and has drawn comparisons to the rapid development of mRNA vaccines during the COVID-19 pandemic.
Political and Policy Implications
The breakthrough arrives as debates over vaccine mandates and public health funding continue to roil Washington. While the Trump administration has pushed for a slimmed-down childhood vaccine schedule, the success of mRNA technology in oncology could reshape federal investment in personalized medicine. Critics of the administration's vaccine skepticism have pointed to such advances as evidence of the technology's broader potential.
Meanwhile, the widening gap in federal funding for special education under the Individuals with Disabilities Education Act has drawn attention to how government commitments—or lack thereof—affect research priorities. Some analysts argue that sustained federal support for biomedical innovation, including mRNA platforms, could accelerate cures for cancer and other diseases.
The melanoma vaccine is still investigational and has not yet received regulatory approval. Moderna and Merck plan to submit the data to the Food and Drug Administration as part of ongoing discussions about a potential accelerated approval pathway.
